Primary Peritoneal

Treatment Stage Protocol Title ClinicalTrials.Gov Link Penn Research Coordinator Am I Eligible?
Stage II-IV Newly Diagnosed  GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

NCT04095364

Destany Fields

Eligibility Criteria 
Recurrent GOG 3104: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy NCT06486441 Shavon Rochester Eligibility Criteria
Recurrent GOG 3096: A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug
Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025 Kristina Powell Eligibility Criteria
Recurrent Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study) NCT04855656 Andrea Standish, RN  Eligibility Criteria
Recurrent ATRIN: A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors NCT04905914 Andrea Standish, RN  Eligibility Criteria
Recurrent GOG 3066: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04814108 Kristina Powell Eligibility Criteria 
Recurrent STAR-101: A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma NCT05568680 Andrea Standish, RN Eligibility Criteria
Recurrent NP-G2-044-P2-01: NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies NCT05023486 Shavon Rochester

Eligibility Criteria

Recurrent NRG-GY031: A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer NCT05950464 Andrea Standish, RN

ON HOLD

Eligibility Criteria

Recurrent Phase 1/2 Study of REGN5668 (MUC16 X CD28, A Costimulatory Bispecific) Administered in Combination with Cemiplimab or REGN4018 (MUC16 X CD3) NCT04590326 Katie Hayes, RN Eligibility Criteria
Maintenance UPROAR: A phase II evaluation of maintenance therapy combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer NCT05887609 Kristina Powell Eligibility Criteria